XENETIC BIOSCIENCES, INC. Unrealized Gain (Loss) on Derivatives
XENETIC BIOSCIENCES, INC. (XBIO) reported Unrealized Gain (Loss) on Derivatives of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2018-03-30
- XENETIC BIOSCIENCES, INC. unrealized gain (loss) on derivatives for the quarter ending 2017-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. unrealized gain (loss) on derivatives for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. unrealized gain (loss) on derivatives for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. unrealized gain (loss) on derivatives for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. unrealized gain (loss) on derivatives for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- XENETIC BIOSCIENCES, INC. unrealized gain (loss) on derivatives for fiscal 2016 was $2.13M.
- XENETIC BIOSCIENCES, INC. unrealized gain (loss) on derivatives for fiscal 2015 was -$2.13M.
- XENETIC BIOSCIENCES, INC. unrealized gain (loss) on derivatives for fiscal 2014 was $0.00.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $0.00 derived: sum of 2 quarters · filed 2018-03-30 | $0.00 derived: sum of 3 quarters · filed 2018-03-30 | $0.00 10-K · filed 2018-03-30 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-14 | $0.00 derived: sum of 2 quarters · filed 2017-11-14 | $0.00 10-Q · filed 2017-11-14 | -$21.47K derived: sum of 4 quarters · filed 2018-03-30 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | -$21.47K derived: sum of 3 quarters · filed 2018-03-30 | $219.82K derived: sum of 4 quarters · filed 2018-03-30 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 | -$21.47K derived: sum of 2 quarters · filed 2018-03-30 | $219.82K derived: sum of 3 quarters · filed 2018-03-30 | $1.99M derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-12-31 | -$21.47K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $219.82K derived: sum of 2 quarters · filed 2018-03-30 | $1.99M derived: sum of 3 quarters · filed 2018-03-30 | $2.13M 10-K · filed 2018-03-30 |
| 2016-09-30 | $241.30K 10-Q · filed 2017-11-14 | $2.01M derived: sum of 2 quarters · filed 2017-11-14 | $2.15M 10-Q · filed 2017-11-14 | $1.37M derived: sum of 4 quarters · filed 2017-11-14 |
| 2016-06-30 | $1.77M 10-Q · filed 2017-08-14 | $1.91M 10-Q · filed 2017-08-14 | $1.12M derived: sum of 3 quarters · filed 2017-08-14 | -$219.83K derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-03-31 | $136.01K 10-Q · filed 2017-05-15 | -$644.56K derived: sum of 2 quarters · filed 2017-05-15 | -$1.99M derived: sum of 3 quarters · filed 2017-05-15 | -$1.99M derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | -$780.58K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | -$2.13M derived: sum of 2 quarters · filed 2017-03-31 | -$2.13M derived: sum of 3 quarters · filed 2017-03-31 | -$2.13M 10-K · filed 2017-03-31 |
| 2015-09-30 | -$1.34M 10-Q · filed 2016-11-14 | -$1.34M derived: sum of 2 quarters · filed 2016-11-14 | -$1.34M 10-Q · filed 2016-11-14 | -$1.34M derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | $0.00 10-Q · filed 2016-08-15 | $0.00 10-Q · filed 2016-08-15 | $0.00 derived: sum of 3 quarters · filed 2016-08-15 | $0.00 derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-16 | $0.00 derived: sum of 2 quarters · filed 2016-05-16 | $0.00 derived: sum of 3 quarters · filed 2016-05-16 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | $0.00 10-K · filed 2016-03-30 | |
| 2014-09-30 | $0.00 10-Q · filed 2015-11-16 | $0.00 10-Q · filed 2015-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |